DGS Capital Management LLC Sells 302 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

DGS Capital Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,272 shares of the biopharmaceutical company’s stock after selling 302 shares during the period. DGS Capital Management LLC’s holdings in Gilead Sciences were worth $302,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth approximately $25,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the second quarter valued at about $33,000. Finally, Friedenthal Financial purchased a new stake in shares of Gilead Sciences during the third quarter worth about $50,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $93.07 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm’s 50-day moving average is $91.74 and its 200 day moving average is $84.86. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a market capitalization of $115.99 billion, a price-to-earnings ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. The Goldman Sachs Group boosted their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.